Conflicting results have been obtained regarding the effect of enzalutamide, an anti-androgen molecule approved for the treatment of castration-resistant PCa patients, on the regulation of TMPRSS2 expression. The gene discussed is TMPRSS2; the disease is posterior cortical atrophy.